Riskpilot← Back to searchSign inGet full accessMedirob AB
ABDissolvedOrg 5566940374Manufacture of medical and dental instruments and supplies · NACE 3250Est. 20050 employees
Revenue 2022
SEK 35K
-90% vs 2021
EBITDA margin
-17.1%
-103% vs 2021
Equity ratio
91.7%
Financial strength
Net profit 2022
SEK -10K
-113% vs 2021
| Revenue | SEK 35K | -90% |
| EBITDA | SEK -6K | -103% |
| Net profit | SEK -10K | -113% |
| Total assets | SEK 169K | -53% |
| Equity | SEK 155K | -6% |
| Employees | 0 | — |
Legal name
Medirob AB
Org number
5566940374
Legal form
Aktiebolag
NACE code
3250 · Manufacture of medical and dental instruments and supplies
Founded
15 december 2005
Share capital
SEK 100 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2022-04-30
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Aktiebolaget ska bedriva utveckling, tillverkning och försäljning av medicinska produkter samt idka därtill knuten konsult- verksamhet samt därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | 0 | 100 | 411 | 336 | 35 |
| Staff expenses | — | — | — | — | — | — | — |
| EBITDA | 18 | −24 | −17 | 2 | 11 | 236 | −6 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −1 | −4 | −4 |
| EBIT | 18 | −24 | −17 | 2 | 10 | 232 | −10 |
| Net financials | — | — | — | — | — | — | — |
| Profit before tax | 18 | −24 | −17 | 2 | 10 | 82 | −10 |
| Tax | −0 | −0 | −0 | −0 | −0 | −4 | −0 |
| Net profit | 18 | −24 | −17 | 2 | 10 | 78 | −10 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Total assets | 132 | 94 | 86 | 121 | 418 | 357 | 169 |
| Equity | 116 | 92 | 75 | 77 | 87 | 165 | 155 |
| Long-term debt | 0 | 0 | 0 | 0 | 170 | 0 | 0 |
| Short-term debt | 16 | 2 | 11 | 44 | 161 | 192 | 14 |
| Total debt | 16 | 2 | 11 | 44 | 331 | 192 | 14 |
EBITDA margin
-17.1%
This company
15.8%
Market median
-208% vs market
20162022
Equity ratio
91.7%
This company
38.2%
Market median
+140% vs market
20162022
Return on equity
-6.5%
This company
18.4%
Market median
-135% vs market
20162022
Net profit margin
-28.6%
This company
8.1%
Market median
-453% vs market
20162022
Asset turnover
0.21×
This company
1.12×
Market median
-81% vs market
20162022
Debt / equity
0.09×
This company
0.62×
Market median
+85% vs market
20162022
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-05-01 – 2021-04-30
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-05-01 – 2020-04-30
- Annual report 2019Filed via Bolagsverket / SCB · Period 2018-05-01 – 2019-04-30
- Annual report 2018Filed via Bolagsverket / SCB · Period 2017-05-01 – 2018-04-30
- Annual report 2017Filed via Bolagsverket / SCB · Period 2016-05-01 – 2017-04-30
- Annual report 2016Filed via Bolagsverket / SCB · Period 2015-01-01 – 2016-04-30
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2022 | — | — | |
| Board of Directors | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Moroco Aktiebolag | Company | 100.0% | 100.0% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Moroco Aktiebolag
Medirob AB Board members of Medirob AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Rolf Andreas Sjödin | Deputy Board Member | 0 companies |
| Lars Olof Hellman | Board of Directors | 0 companies |